Markus Muellner

Markus is the CTO of PhoreMost Ltd, a Cambridge Biotech startup using a novel target discovery platform to find ways of drugging the undruggable. He set up PhoreMosts’ functional proteomics technology platform and is heading the R&D team to drive target discovery screens both for internal as well as external programs.

Markus has a background in wet lab and computational approaches in cancer drug target discovery and functional genetics. He holds an engineer’s degree, an MSc. in Life Sciences from the University of Vienna (Analytical Chemistry) and a PhD from the Medical University of Vienna (Medical Chemistry).

Prior to PhoreMost he worked at the Center for Molecular Medicine (CeMM) establishing a novel multiplexing platform that led to the discovery of NOTCH1/MYC as a factor in PI3K inhibitor resistance and established haplo-genetic screens to elucidate drug uptake mechanisms in human cancer cells. In 2015 he left Vienna and moved to Cambridge, UK to join PhoreMost